Todd Schlesinger, MD, FAAD

Dr. Todd Schlesinger is a board-certified dermatologist, Mohs surgeon and clinical investigator. He completed his residency at the Cleveland Clinic Foundation and is the founder of a three-office dermatology and dermatologic surgery practice (now part of Epiphany Dermatology) and clinical research center. His areas of research focus are inflammatory dermatoses, cutaneous oncology, and cosmetic dermatology. He is the author of over 100 peer-reviewed publications as well as several book chapters and numerous presentations and posters at national and international conferences. He is past president of the South Carolina Medical Association, the South Carolina Academy of Dermatology and Dermatologic Surgery, and the past Editor in Chief of the AAD’s ongoing member CME program Dialogues in Dermatology. He is currently serving as a member of the AAD Board of Directors, one of three Scientific Directors at Facial Aesthetic Conference and Exhibition (F.A.C.E.) in London, a Scientific Committee Member at IMCAS World Conference, and on the Advisory Board of LiVDerm. He was inducted to the American Dermatological Association in 2025 and will be inducted to the Noah Worcester Dermatological Society in 2026.
Financial relationships
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:Avant Health, Chronicle Medical Software, Derma-Gene, SkinCure OncologyDate added:11/20/2025Date updated:11/20/2025
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:Almirall, Galderma, Regeneron, Abbvie, SUN, Feldan Therapeutics, RBC, Lilly, Janssen,Novartis, Pfizer, SkinCure Oncology, VerricaDate added:11/20/2025Date updated:11/20/2025
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:Almirall, Galderma, Regeneron, Abbvie, Medicus, SUNDate added:11/20/2025Date updated:11/20/2025
-
Attribution:SelfType of financial relationship:SpeakerIneligible company:Almirall, Arcutis, Benev, Galderma, Regeneron, BMS, UCB. SUN, Lilly, JanssenDate added:11/20/2025Date updated:11/20/2025

Facebook
X
LinkedIn
Forward